Syndax Pharmaceuticals Gains 0.98%, But Still Lags Market.
February 3, 2023
Trending News 🌧️
Syndax Pharmaceuticals ($NASDAQ:SNDX) is a biopharmaceutical company specializing in the development of cancer therapeutics. The company’s stock closed at $28.98 in the latest trading session, representing a 0.98% increase from the previous close. Despite this small gain, Syndax Pharmaceuticals’ stock still lagged behind the overall market. Syndax Pharmaceuticals is focused on the development of innovative cancer therapeutics, including small molecules and monoclonal antibodies. The company is committed to improving the lives of patients by bringing new treatment options to market. Its most advanced drug candidate, entinostat, is being investigated in multiple clinical trials for several types of cancer, including breast cancer and lymphoma.
The company is also facing increased competition from larger pharmaceutical companies who are entering the market for cancer therapeutics. Despite its recent struggles, Syndax Pharmaceuticals remains committed to developing innovative treatments for cancer patients. The company is currently focused on advancing its pipeline of novel cancer therapeutics and is continuing to explore new collaborations and partnerships with other biopharmaceutical companies. Investors should keep a close eye on the company’s progress as it looks to regain investor confidence with its promising pipeline of potential treatments.
Stock Price
Syndax Pharmaceuticals has not had the success that investors had hoped for despite some positive gains in stock value. On Thursday, the stock opened at $29.2 and closed at $28.6, down by 1.5% from its prior closing price of 29.0. This puts the stock at a 0.98% gain overall, however it still lags behind the general market. At present, the media sentiment towards Syndax Pharmaceuticals is mostly negative. This could be due to the fact that their stock is underperforming compared to other companies in the industry, or perhaps due to other factors outside of their control. Whatever the cause, it’s clear that investors are cautious when it comes to investing in Syndax Pharmaceuticals. It remains to be seen if Syndax Pharmaceuticals will be able to turn things around and regain investor confidence. In order to do so, they will need to make strategic investments and focus on developing products and services that will appeal to their target market.
Additionally, they must ensure that they are responding quickly and effectively to any negative press or news surrounding their company. At this point, Syndax Pharmaceuticals has a long road ahead of them if they want to make a successful return to the market. While there is still hope for them to make a recovery, it is important that they are mindful of their stock performance and adjust their strategies accordingly in order to remain competitive. Only time will tell if they are able to realize their potential and gain investor confidence once again. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Syndax Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 126.58 | -13.95 | -11.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Syndax Pharmaceuticals. More…
| Operations | Investing | Financing |
| -10.07 | -108.52 | 118.53 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Syndax Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 359.69 | 21.59 | 5.62 |
Key Ratios Snapshot
Some of the financial key ratios for Syndax Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 337.0% | – | -8.6% |
| FCF Margin | ROE | ROA |
| -8.1% | -1.9% | -1.9% |
Analysis
GoodWhale is a great tool to analyze the fundamentals of SYNDAX PHARMACEUTICALS. According to the Risk Rating, it is a high risk investment, both in terms of financial and business aspects. GoodWhale has detected 3 risk warnings in balance sheet, cashflow statement, and non-financial areas. It is important to note that the company’s financial position is only as good as the information it provides. Financial statements must be read carefully to detect any discrepancies or irregularities in the accounting of the company. GoodWhale also provides users with detailed analysis of the company’s risk profile. This includes an assessment of the company’s liquidity and debt levels, as well as its capital structure and operational performance. GoodWhale also provides investors with detailed data on the company’s key financial metrics such as profitability, cash flow, and liquidity. This allows investors to make informed decisions on their investments in SYNDAX PHARMACEUTICALS. Furthermore, GoodWhale also helps users identify any legal or regulatory issues that may affect the company’s business. To make the most out of GoodWhale, users need to become a registered user. This will give them access to all the data and insights necessary to make a well-informed investment decision. By using GoodWhale’s analysis, investors can gain a better understanding of SYNDAX PHARMACEUTICALS and make better decisions about their investments. More…
Peers
The biopharmaceutical industry is highly competitive, with companies vying for market share in the development and commercialization of innovative therapies. The company’s main competitors are Fate Therapeutics Inc, Arvinas Inc, and Mirati Therapeutics Inc. All three companies are engaged in the development of cancer therapies, with each company having its own proprietary technology and product pipeline.
– Fate Therapeutics Inc ($NASDAQ:FATE)
Fate Therapeutics is a biopharmaceutical company that develops immunotherapies for cancer and other diseases. The company’s immunotherapies are based on its proprietary platform of induced pluripotent stem cells (iPSCs). Fate Therapeutics’ iPSC platform allows the company to generate fully differentiated, functional immune cells from a patient’s own cells. These immune cells can then be used to treat the patient’s disease. The company’s lead product candidates are FT516, an iPSC-derived natural killer cell therapy, and FT767, an iPSC-derived T cell therapy. Fate Therapeutics is also developing FT819, an iPSC-derived myeloid cell therapy.
– Arvinas Inc ($NASDAQ:ARVN)
Arvinas Inc is a pharmaceutical company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 2.35B as of 2022 and a Return on Equity of -20.23%. Arvinas was founded in 2013 and is headquartered in New Haven, Connecticut.
– Mirati Therapeutics Inc ($NASDAQ:MRTX)
Mirati Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel small molecule therapeutics to treat cancer. The company’s market cap as of 2022 is 3.7B and its ROE is -33.77%. The company’s main products are targeted cancer therapies, which are designed to selectively target and kill cancer cells while sparing normal cells.
Summary
Syndax Pharmaceuticals has been performing relatively poorly in the market compared to other companies. Despite seeing a 0.98% increase in stock value, it still lags behind the overall market. Media sentiment towards the company has been mostly negative.
For investors considering putting money into Syndax Pharmaceuticals, they should take caution and thoroughly analyze the company before making any decisions. It is important to look at the company’s financials, management team, and potential for long-term growth before investing.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
